Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Foresees 82% Profit Dip in FY2019 as Gilenya Feud Weighs
May 13, 2019
- 70% of Drug Makers Shave New Grad Hiring, 100-Plus Recruits at Only 3 Firms: Jiho Survey
May 13, 2019
- Eisai Nabs Japan Distribution Rights to MTX SC Injection
May 13, 2019
- Alzheimer's Consortium Selects Elenbecestat, BAN2401 for Prevention Studies
May 13, 2019
- Entyvio’s SC Form Accepted by US FDA for Review: Takeda
May 13, 2019
- Sunovion’s Schizophrenia Agent Awarded US Breakthrough Therapy Designation
May 13, 2019
- Shionogi's FY2018 Sales Up 5.5% on HIV Royalties, Xofluza Notches 26.3 Billion Yen
May 10, 2019
- Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
- Eisai to Invest 15 Billion Yen to Excavate Innovative Technology; 1st Pact Signed with App Developer
May 10, 2019
- Takeda to Divest Dry Eye Drug to Novartis for US$5.3 Billion
May 9, 2019
- Japan Generic Makers Cutting Back on New Grad Hiring in Near-Saturated Market: Jiho Survey
May 9, 2019
- Kissei Braced for 65% Sales Fall for Urief on Generic Onslaught; Exec Admits Uphill Battle for Nesp Biosimilar
May 9, 2019
- Sumitomo Dainippon to Set Up Cell Therapy Hub in San Diego
May 9, 2019
- DS-8201 Delivers in PII Breast Cancer Study: Daiichi Sankyo/AZ
May 9, 2019
- Eisai Kicks Off Joint Program with UK Institution to Support Dementia Research
May 9, 2019
- Bioverativ Japan Now Merged into Sanofi
May 8, 2019
- Eisai, Purdue Wind Up Partnership for Insomnia Drug Lemborexant
May 8, 2019
- Shionogi, AI Startup Tie Up to Develop Influenza Diagnostic Device
May 8, 2019
- Japan Generic Market to Reach 1.2 Trillion Yen by 2022, Biosimilars, AG Market to Expand Too: Fuji Keizai
May 7, 2019
- Daiichi Sankyo Skips Pre-Verification for Vaccine Sterility Test, No Safety Concerns Found
May 7, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…